Historically, multiple sclerosis (MS) has been considered a disease seen largely in the non-Hispanic white population, but more recent research has proven that is not the case. In minority populations, MS is distinguished by differences in disease onset, presentation, and course. The clinical picture for minority patients is also complicated, but the fact is that optimization of care for these patients is often difficult because they are underrepresented in clinical trials, resulting in limited evidence from which clinicians can base decisions about treatment and follow-up.

The management of IBD remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Anita Afzali presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.

It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Hudesman presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.

Chronic hepatitis B (CHB) is a serious viral disease associated with significant and preventable morbidity and mortality. There are an estimated 850,000-2.2 million persons living with CHB. Left untreated, up to 40% of those with CHB develop significant clinical consequences, including cirrhosis, liver failure, or HCC, and approximately 15% to 25% die from liver failure or liver cancer. Experts discuss diagnosis, treatment and management.

Vaginal infections are among the most common reasons why women in the United States seek medical care. These infections are typically characterized by discharge, itching, or odor. Although vaginal discharge symptoms are common, diagnosis of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginalis (TV) is not standardized. As a result, diagnostic approaches and the suitability of treatment for vaginal discharge syndromes in community practices remain inadequate.

Skepticism regarding the use of real-world evidence continues to exist among oncologists, but in actuality, real-world studies can provide information that may aid clinicians in Europe who are treating patients with HR-positive/HER2-negative metastatic breast cancer, especially regarding the use of CDK 4/6 inhibitors.

This discussion focuses on the fundamental value that real-world evidence can provide in support of randomized clinical trials and how oncologists can best incorporate these data into current clinical practice.

Chronic hepatitis C is a serious viral disease associated with significant and preventable morbidity and mortality, affecting an estimated 3.5 to 5 million patients. This activity will focus on improving the outcomes among patients with chronic hepatitis C by increasing awareness of its epidemiology, diagnosis and management, guidelines for antiviral treatment, and the management of patients who have achieved SVR.

Approximately 3 to 4 percent of the non-small cell lung cancer patient population as a whole harbors MET exon 14 skipping mutations that result in increased MET kinase protein levels and a constitutively active pathway. There is increasing excitement that these mutations, as well as MET gene amplification, can be specifically targeted with MET-directed approaches. Join us as Drs. Everett Vokes and Ross Camidge discuss both the dysregulation of the MET pathway in non-small cell lung cancer and the therapeutic potential of small molecule MET kinase inhibitors.

EGFR tyrosine kinase inhibitors, or EGFR-TKIs, have resulted in dramatic improvements for patients with EGFR-mutant advanced non-small cell lung cancer. However, acquired resistance continues to limit their long-term benefit. While often due to an acquired T790M mutation, dysregulation of the MET pathway in non-small cell lung cancer is emerging as an important participant in acquired EGFR-TKI resistance. Join us as we discuss the dysregulation of the MET pathway in non-small cell lung cancer, as well as the therapeutic potential of MET pathway inhibitors.

Learn insightful information around the treatment of non-small cell lung cancer (NSCLC) with thoughtful consideration of novel sampling applications, genomic mutations, and resistance mechanisms.